| scholarly article | Q13442814 |
| P50 | author | Javier Martín-Broto | Q92897377 |
| P2093 | author name string | Amancio Carnero | |
| Blanca Felipe-Abrio | |||
| Marco Perez | |||
| Sandra Muñoz-Galván | |||
| José Manuel García-Heredia | |||
| P2860 | cites work | The epidemiology of sarcoma | Q21195878 |
| RAD51 localization and activation following DNA damage | Q24675478 | ||
| Emergence of micronuclei and their effects on the fate of cells under replication stress | Q27331852 | ||
| Interactions of MAP17 with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells | Q28184044 | ||
| ATM phosphorylates histone H2AX in response to DNA double-strand breaks | Q28188651 | ||
| NUMB controls p53 tumour suppressor activity | Q28263413 | ||
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| Rat kidney MAP17 induces cotransport of Na-mannose and Na-glucose in Xenopus laevis oocytes | Q30948630 | ||
| Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. | Q31975442 | ||
| A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. | Q33161027 | ||
| Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses | Q33415400 | ||
| Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. | Q33432279 | ||
| Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition | Q33603605 | ||
| PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models | Q33617922 | ||
| TNF-α contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT | Q33813215 | ||
| Replication stress induces micronuclei comprising of aggregated DNA double-strand breaks | Q33883336 | ||
| H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. | Q34089263 | ||
| Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. | Q34320295 | ||
| Role of poly(ADP-ribose) formation in DNA repair | Q34359946 | ||
| MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival | Q34589895 | ||
| MAP17 overexpression is a common characteristic of carcinomas | Q34617889 | ||
| MAP17 enhances the malignant behavior of tumor cells through ROS increase | Q34634409 | ||
| Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker | Q34852332 | ||
| Focus on sarcomas | Q34872301 | ||
| Caspase-3-independent apoptotic pathways contribute to interleukin-32γ-mediated control of Mycobacterium tuberculosis infection in THP-1 cells | Q35147724 | ||
| Mechanisms of sarcoma development | Q35210018 | ||
| MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer. | Q35828640 | ||
| Caspase activation, inhibition, and reactivation: a mechanistic view | Q35845173 | ||
| Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. | Q35895214 | ||
| Advances in sarcoma genomics and new therapeutic targets | Q35993346 | ||
| Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53. | Q36237705 | ||
| The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin | Q36326279 | ||
| γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. | Q36409165 | ||
| Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. | Q36562082 | ||
| Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. | Q36953271 | ||
| Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival | Q37362503 | ||
| Reactive oxygen species in cancer | Q37431048 | ||
| Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy. | Q37665411 | ||
| Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. | Q37680260 | ||
| Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). | Q37687113 | ||
| PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration | Q37822920 | ||
| The DNA damage response and cancer therapy | Q37977004 | ||
| MAP17 and the double-edged sword of ROS. | Q37998770 | ||
| Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics. | Q38369403 | ||
| The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. | Q38718226 | ||
| MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer | Q38891466 | ||
| p38α limits the contribution of MAP17 to cancer progression in breast tumors | Q39408183 | ||
| 53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms | Q39468621 | ||
| MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation | Q40098263 | ||
| Levels of p27(kip1) determine Aplidin sensitivity | Q40146329 | ||
| Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where? | Q40778763 | ||
| Germline Mutations in Cancer Predisposition Genes are Frequent in Sporadic Sarcomas | Q41637022 | ||
| MAP17, a ROS-dependent oncogene | Q42323237 | ||
| The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment | Q47122756 | ||
| Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. | Q49279543 | ||
| PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. | Q50277644 | ||
| Screening and identification of distant metastasis-related differentially expressed genes in human squamous cell lung carcinoma. | Q51541269 | ||
| The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. | Q55037005 | ||
| Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases. | Q55227686 | ||
| A review of soft-tissue sarcomas: translation of biological advances into treatment measures. | Q55265062 | ||
| A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation | Q57569610 | ||
| Tumor suppressors BTG1 and BTG2: Beyond growth control | Q57797688 | ||
| Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53 | Q57975487 | ||
| MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma | Q58770545 | ||
| MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy | Q58779402 | ||
| Expression of γ-H2AX in endometrial carcinomas: an immunohistochemical study with p53 | Q64386984 | ||
| ROS and the DNA damage response in cancer | Q64388266 | ||
| Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group | Q64388974 | ||
| Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis | Q73642988 | ||
| PARP inhibitors in ovarian cancer | Q90450743 | ||
| ATM in DNA repair in cancer | Q91830786 | ||
| The DNA Damaging Revolution: PARP Inhibitors and Beyond | Q92109728 | ||
| Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review | Q92372923 | ||
| A decade of clinical development of PARP inhibitors in perspective | Q92890485 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P921 | main subject | doxorubicin | Q18936 |
| olaparib | Q7083106 | ||
| P304 | page(s) | 195 | |
| P577 | publication date | 2020-09-23 | |
| P1433 | published in | Signal Transduction and Targeted Therapy | Q108821959 |
| P1476 | title | Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment | |
| P478 | volume | 5 |
Search more.